A 2026 AB10015 post-hoc preprint reported 42.3% 5-year survival from amyotrophic lateral sclerosis symptom onset among patients originally assigned to masitinib 4.5 mg/kg/day with riluzole. The number is large for ALS, but the long-term comparison is historical and modeled rather than randomized placebo follow-up.1 Research Highlights 42.3% reached 5 years from onset: Ludolph et al. …
A 2026 cerebrospinal-fluid proteomics preprint involving 87 amyotrophic lateral sclerosis (ALS) patients, 89 healthy controls, and 61 neurological controls reported 399 ALS candidate proteins, complement markers that tracked disease stage, and a 5-protein panel that classified ALS vs. healthy controls with ROC AUC 0.95 after the best-known neurodegeneration markers were removed.1 Research Highlights CSF proteomics …
A 2026 PRO-ACT analysis of amyotrophic lateral sclerosis (ALS) trial data found a signal that ordinary ALSFRS total-score slopes cannot even express: Shannon entropy trajectories diverged between pooled active and placebo arms, including a 5-month delay in peak Fine Motor distributional spread for active-arm patients.1 Research Highlights Entropy found an endpoint-level signal: Rodriguez analyzed 7,512 …